

Edgar Filing: AMPLIDYNE INC - Form 10QSB

AMPLIDYNE INC
Form 10QSB
August 23, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-QSB

- QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2004.
- TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.

FOR THE TRANSITION PERIOD FROM _____ TO _____

Commission File Number 0-21931

AMPLIDYNE, INC.

(Exact name of small business issuer as specified in its charter)

DELAWARE

(State or other jurisdiction of
incorporation or organization)

22-3440510

(I.R.S. Employer
Identification No.)

59 LaGrange Street
Raritan, New Jersey 08869
(Address of principal executive offices)

(908) 253-6870

(Issuer's telephone number)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

The number of shares outstanding of the Issuer's Common Stock, \$.0001 Par Value, as of August 20, 2004 was 10,376,500.

AMPLIDYNE, INC.

FORM 10-QSB

SIX MONTHS ENDED June 30, 2004

TABLE OF CONTENTS

Edgar Filing: AMPLIDYNE INC - Form 10QSB

PART I - FINANCIAL INFORMATION

Item 1	FINANCIAL STATEMENTS (UNAUDITED): -----	
	Balance Sheets.....	1-2
	Statements of Operations.....	3
	Statement of Cash Flows.....	4
	Statement of Changes in Stockholders' Deficiency.....	5
	Notes to Financial Statements.....	6-10
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations.....	12-14
Item 3.	Controls and Procedures.....	14

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings.....	15
Item 2.	Change in Securities.....	15
Item 5.	Other Information.....	15
Item 6.	Exhibits.....	16
	Signatures.....	16

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AMPLIDYNE, INC. BALANCE SHEETS

ASSETS	(UNAUDITED)	Decem
	June 30	2
	2004	2
	-----	-----
CURRENT ASSETS		
Cash	\$ 15,465	\$
Accounts receivable, net of allowance for doubtful accounts of \$262,000 and \$143,000 in 2004 and 2003, respectively	57,854	9
Inventories	348,520	40
Prepaid expenses and other	--	1
	-----	-----
	-----	-----
Total current assets	421,839	51

Edgar Filing: AMPLIDYNE INC - Form 10QSB

PROPERTY AND EQUIPMENT - AT COST		
Machinery and equipment	565,629	56
Furniture and fixtures	43,750	4
Autos and trucks	66,183	6
Leasehold improvements	8,141	
	-----	-----
	683,703	68
Less accumulated depreciation and amortization	(666,627)	(64)
	-----	-----
	17,076	3
	-----	-----
SECURITY DEPOSITS AND OTHER NON-CURRENT ASSETS	35,625	3
	-----	-----
TOTAL ASSETS	\$ 474,540	\$ 58
	=====	=====

Note: The balance sheet at December 31, 2003 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

The accompanying notes are an integral part of these financial statements

-1-

AMPLIDYNE, INC.
BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

		(UNAUDITED)
		June 30
		2004

CURRENT LIABILITIES		
Overdraft	\$	--
Note payable in connection with Phoenix investor rescission agreement		40,000
Convertible notes payable pursuant to Lee financing agreement		250,000
Customer advances		36,878
Accounts payable		488,817
Accrued expenses and other current liabilities		239,027
Loans payable - officers		329,228

Total current liabilities		1,383,950
Other convertible notes payable		21,573

TOTAL LIABILITIES		1,405,523

STOCKHOLDERS' DEFICIENCY		
Common stock - authorized, 25,000,000 shares of \$.0001 par value;		

Edgar Filing: AMPLIDYNE INC - Form 10QSB

shares 10,376,500 and 10,376,500 shares issued and outstanding at
June 30, 2004 and December 31, 2003, respectively

Additional paid-in capital	1,038	22,503,014
Accumulated deficit		(23,435,035)
		(930,983)
		\$ 474,540

Note: The balance sheet at December 31, 2003 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

The accompanying notes are an integral part of these financial statements

-2-

AMPLIDYNE, INC. STATEMENTS OF OPERATIONS (UNAUDITED) THREE AND SIX MONTHS ENDED JUNE 30

	Three Months Ended June 30	
	2004	2003
Net sales	\$ 240,226	363,904
Cost of goods sold	223,367	278,925
Gross profit	16,859	84,979
Operating expenses		
Selling, general and administrative	109,033	216,940
Research, engineering and development	83,654	97,373
Litigation settlement costs	20,160	--
Operating loss	(195,988)	(229,334)
Nonoperating income (expenses)		
Interest income and other income	--	--
Loss incurred on rescission of prior year agreements with Phoenix to invest in the Company	(40,780)	--
Interest expense	(368)	--
Gain on sale of property and equipment	--	--
Loss before income taxes	(237,136)	(229,334)
Provision for income taxes	2,662	698

Edgar Filing: AMPLIDYNE INC - Form 10QSB

NET LOSS	\$ (239,798)	\$ (230,032)	\$
	=====	=====	==
Net loss per share - basic and diluted	\$ (0.02)	\$ (0.02)	\$
	=====	=====	==
Weighted average number of shares outstanding	10,376,500	10,143,167	
	=====	=====	==

The accompanying notes are an integral part of these financial statements

-3-

AMPLIDYNE, INC.

STATEMENTS OF CASH FLOWS (UNAUDITED)

SIX MONTHS ENDED JUNE 30

	Six Mo Ju 2004

Cash flows from operating activities:	
Net Loss	\$(504,862)

Adjustments to reconcile net loss to net cash used in operating activities	
Depreciation and amortization	20,000
Provision for doubtful accounts	15,260
Litigation settlement costs	20,160
Deferred officer compensation	55,233
Interest accrued on other convertible promissory note	600
Issuance of secured promissory in connection with loss incurred on rescision of agreements with Phoenix to invest in the Company	40,000
Changes in assets and liabilities	
Accounts receivable	18,368
Inventories	59,189
Prepaid expenses and other assets	12,307
Customer advances	23,122
Accounts payable and accrued expense	210,187

Total adjustments	428,182

Net cash (used) for operating activities	(76,680)

Cash flows from investing activities:	
Change in security deposits	--

Net cash provided by (used for) investing activities	--

Cash flows from financing activities:	

Edgar Filing: AMPLIDYNE INC - Form 10QSB

Change in overdraft	(17,855)
Payment of lease obligations	--
Officer loans	17,000
Proceeds from convertible notes received directly in cash pursuant to Lee financing agreement	93,000
Proceeds from other convertible promissory note	--
Net cash provided by financing activities	92,145
NET INCREASE (DECREASE) IN CASH	15,465
Cash at beginning of period	--
Cash at end of period	\$ 15,465
Supplemental disclosures of cash flow information:	
Cash paid for: Interest	\$ --
Income taxes	\$ 5,862
Noncash financing activities:	
Convertible notes issued by Company pursuant to Lee financing agreement	\$ 250,000
Less: Proceeds received directly in cash by Company	93,000
Payment of Company obligations by lender in connection with financing agreement in exchange for convertible notes	\$ 157,000

The accompanying notes are an integral part of these financial statements

-4-

AMPLIDYNE, INC.
STATEMENT OF STOCKHOLDERS' DEFICIENCY
YEAR ENDED DECEMBER 31, 2003 AND SIX MONTHS ENDED JUNE 30, 2004

	PREFERRED STOCK		
	SHARES	PAR VALUE	
BALANCE AT DECEMBER 31, 2002	--	\$ --	9
Net loss for the year ended December 31, 2003			
Issuance of common stock in connection with litigation settled in the year ended December 31, 2002			
BALANCE AT DECEMBER 31, 2003	--	--	10
Net loss for the six months ended June 30, 2004			
Litigation settlement to be paid through the issuance of common stock			

Edgar Filing: AMPLIDYNE INC - Form 10QSB

	-----	-----	-----
BALANCE AT JUNE 30, 2004	--	\$ --	10
	=====	=====	==
	-----	-----	-----
	-----	-----	-----
BALANCE AT DECEMBER 31, 2002	\$ 22,494,924	\$ (21,949,679)	\$
Net loss for the year ended December 31, 2003		(980,494)	
Issuance of common stock in connection with litigation settled in the year ended December 31, 2002	(70)		
	-----	-----	-----
BALANCE AT DECEMBER 31, 2003	22,494,854	(22,930,173)	
THE FOLLOWING INFORMATION IS UNAUDITED:			
Net loss for the six months ended June 30, 2004		(504,862)	
Litigation settlement to be paid through the issuance of common stock	8,160		
	-----	-----	-----
BALANCE AT JUNE 30, 2004	\$ 22,503,014	\$ (23,435,035)	\$
	=====	=====	==

The accompanying notes are an integral part of these financial statements

-5-

AMPLIDYNE, INC.
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS
JUNE 30, 2004

NOTE A - ADJUSTMENTS

In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of (a) results of operations for the three and six month periods ended June 30, 2004 and 2003, (b) the financial position at June 30, 2004, (c) the statements of cash flows for the six month period ended June 30, 2004 and 2003, and (d) the changes in stockholders' deficiency for the six month period ended June 30, 2004 have been made. The results of operations for the three or six months ended June 30, 2004 are not necessarily indicative of the results to be expected for the full year.

NOTE B - UNAUDITED INTERIM FINANCIAL INFORMATION

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for financial statements. For further information, refer to the audited financial statements and notes thereto for the year ended December 31, 2003 included in the Company's Form

Edgar Filing: AMPLIDYNE INC - Form 10QSB

10-KSB filed with the Securities and Exchange Commission on April 14, 2004.

The Company's financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The liquidity of the Company has been adversely affected in recent years by significant losses from operations. As further discussed in Note F, the Company incurred losses of \$504,862 for the six months ended June 30, 2004, has limited cash reserves and has seen its working capital decline by \$476,102 to a deficiency of \$(962,111) since the beginning of the fiscal year. Current liabilities exceed cash and receivables by \$1,310,631 indicating that the Company will have difficulty meeting its financial obligations for the balance of this fiscal year. These factors raise substantial doubt as to the Company's ability to continue as a going concern. Recently, operations have been funded by loans from the Chief Executive Officer and costs have been cut through substantial reductions in labor and operations.

As further discussed in Note F, management is seeking additional financing and intends to aggressively market its products, control operating costs and broaden its product base through enhancements of products. The Company believes that these measures may provide sufficient liquidity for it to continue as a going concern in its present form. Accordingly, the financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern in its present form.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any transactions, agreements or other contractual arrangements that constitute off balance sheet arrangements.

-6-

AMPLIDYNE, INC. NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS JUNE 30, 2004

NOTE C - STOCKHOLDERS' EQUITY

1. WARRANTS AND OPTIONS

At June 30, 2004, the following 945,000 warrants, remained outstanding:

- (1) 20,000 exercisable at \$1.00 through May 2010
- (2) 20,000 exercisable at \$7.00 through December 2004
- (3) 30,000 exercisable at \$6.00 through November 2004
- (4) 50,000 exercisable at \$2.00 through December 2004
- (5) 50,000 exercisable at \$4.00 through December 2004
- (6) 16,000 exercisable at \$1.75 through December 2004
- (7) 41,500 exercisable at \$1.80 through July 31, 2004
- (8) 207,500 exercisable at \$3.00 through July 31, 2004

Edgar Filing: AMPLIDYNE INC - Form 10QSB

- (9) 55,000 exercisable at \$1.20 through September 30, 2004
- (10) 300,000 exercisable at \$2.00 through December 31, 2005
- (11) 75,000 exercisable at \$.96 through March 2007
- (12) 80,000 exercisable at \$1.50 through December 2004.

At June 30, 2004, the Company had employee stock options outstanding to acquire 2,221,000 shares of common stock at exercise prices of \$0.15 to \$3.25.

2. STOCK PURCHASE AND FINANCING AGREEMENTS

On January 28, 2004, the Company entered into a Subscription Agreement (the "Agreement") with Phoenix Opportunity Fund II, L.P. ("Phoenix"), a limited partnership organized under the laws of the State of Delaware, pursuant to which Phoenix agreed to make an aggregate investment of \$100,000 in exchange for 282,700 shares of a newly created class of Series C Convertible Preferred Stock, representing approximately 80% of the Company's outstanding stock on a fully diluted basis. As the Company was required to amend its certificate of incorporation or effect a reverse stock split in order to have sufficient authorized shares to complete the equity financing, Phoenix made an initial investment of \$20,000 in exchange for 54,325 shares of Series C Convertible Preferred Stock, and loaned approximately \$80,000 to the Company with the remaining portion of the equity investment to be completed after recapitalization. Phoenix also entered into a stock restriction agreement with Devendar S. Bains, our former Chairman of the Board, Chief Executive Officer, and Treasurer, pursuant to which Mr. Bains issued an irrevocable proxy to Phoenix until the recapitalization is completed, which, together with the shares received in connection with the initial investment, would have given Phoenix effective control over 53% of the Company's voting stock.

The preferred shares were never issued to Phoenix. Due to a dispute among the Parties with respect to the terms of the loan transaction. The Company and Phoenix agreed to rescind their agreement, and the Company agreed to pay Phoenix: (i) \$20,000 in cash for the funds Phoenix invested, (ii) \$80,000 in cash for the funds which Phoenix lent to the Company, and (iii) \$40,000 for expenses incurred by Phoenix on behalf of the Company. The \$40,000 was paid by delivery of a secured promissory note due March 31, 2005, and bearing interest at the rate of eight percent per annum secured by substantially all the assets of the company. In addition, the Company accepted the resignation of Ramesh S. Akella, Carmen P. Akella, Venkata Maddineni from the Board of Directors of the Company.

-7-

AMPLIDYNE, INC.
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS
JUNE 30, 2004

In a separate transaction, John Lee of Piscataway, NJ ("Lee") entered into a Note Purchase Agreement with the Company by which Lee has agreed to lend the Company an initial \$200,000 and up to an additional \$300,000 in one or more installments on or before October 30, 2004. The Company has agreed to deliver to John Lee convertible promissory notes which are convertible into Series C shares representing approximately 80% of the Company's outstanding stock on a fully diluted basis. Such conversion will take place at such time is able to do so. Messrs. Devendar Bains and Tarlochan Bains are required to devote their full

Edgar Filing: AMPLIDYNE INC - Form 10QSB

business time and attention to the business of the Company for eight (8) years from May 25, 2004. In the event that either Devendar Bains or Tarlochan Bains must leave the employ of the Company for any reason, each agrees that, if requested by the Board of Directors of the Company, he will use his best efforts to find a qualified replacement for himself acceptable to the Board of Directors, and that he will not engage in a business competitive with the Company for a period of eight (8) years. On May 25, 2004, Lee loaned the Company \$200,000, and was issued two convertible promissory notes which will be convertible in the aggregate into Series C shares representing approximately 32% of the Company's outstanding stock on a fully diluted basis, if and when converted. If not converted, the notes are payable on demand, provided that demand cannot be made before December 31, 2004, unless the Company is in default of the Note Purchase Agreement. Of the \$200,000 loaned to the Company, \$100,000 was used to pay Phoenix in connection with the rescission described above, \$45,000 was used to make a final payment in resolution of litigation with High Gain Antenna Co. Ltd. of Korea, and to pay associated bank fees, \$12,000 was used to pay legal fees and \$43,000 was used for working capital purposes.

NOTE D - LOSS PER SHARE

The Company complies with the requirements of the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS No. 128"). SFAS No. 128 specifies the compilation, presentation and disclosure requirements for earnings per share for entities with publicly held common stock or potential common stock. Net loss per common share - basic and diluted is determined by dividing the net loss by the weighted average number of common stock outstanding.

Net loss per common share - diluted does not include potential common shares derived from stock options and warrants (see Note C) because they are antidilutive.

NOTE E - LITIGATION

From time to time, the Company is party to what it believes are routine litigation and proceedings that may be considered as part of the ordinary course of its business. Except for the proceedings noted below, the Company is not aware of any pending litigation or proceedings that could have a material effect on the Company's results of operations or financial condition.

1. The Company (as well as an officer and director of the Company) is a defendant in a complaint brought in November 2003 in the Circuit Court of the State of Florida (17th Judicial District, Broward County) alleging fraud and seeking relief for unspecified damages and costs associated with an aborted plan of merger. On June 29, 2004, the Company filed a Motion to Dismiss the lawsuit of V-Link, inc. against the Company.

2. The Company (as well as an officer and director of the Company) was a defendant in a complaint brought in the Superior Court of New Jersey, Law Division, Somerset County, by High Gain Antenna Co., Ltd. of Korea in November 2000. In connection with a Stipulation of Settlement and Release entered into in January 2003 before the Superior Court of New Jersey, the Company has fulfilled its obligations and has received a warrant of satisfaction of judgment from opposing counsel dated June 6, 2004.

-8-

Edgar Filing: AMPLIDYNE INC - Form 10QSB

3. In June 2004, the Company entered into a Settlement Agreement with Wayne Fogel, et al, before the United States District Court in Tampa, Florida. The settlement provides for the following obligations by the Company to Mr. Fogel: (1) payment of \$12,000 by July 14, 2004; (2) issuance of 250,000 shares of restricted common stock by July 14, 2004 and; (3) the shipment of specified items of inventory valued at approximately \$22,000. The agreement further calls for the issuance of common stock of one share for each \$1 of inventory not delivered in lieu of the inventory in the event the company cannot deliver. Since non-delivery of the specified items is definite, the financial statements provide for the issuance of 22,000 additional shares. All shares in connection with this settlement are valued at the publicly traded market value of \$.05 on the date of the transaction, less a discount of 40% for the restriction on sale.

4. In April 2004, a law firm filed a judgement against the Company in the amount of approximately \$40,000 in connection with non-payment of legal fees owed to it. Inasmuch as this is a perfection of an already recorded liability, management does not believe that the judgement will have a material impact on the financial position of the Company.

NOTE F - LIQUIDITY

The Company's financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The liquidity of the Company has been adversely affected in recent years by significant losses from operations. The Company has incurred losses of \$239,798 and \$230,032 for the six months ended June 30, 2004 and 2003, respectively.

With little remaining cash and no near term prospects of private placements, options or warrant exercises (other than the Convertible Notes) and reduced revenues, we believe that we will have great difficulty meeting our working capital needs over the next 12 months. The Company is presently dependent on cash flows generated from sales and financing under the Note Purchase Agreement described in Note C.2. Our failure to consummate a merger with an appropriate partner or to substantially improve our revenues will have serious adverse consequences and, accordingly, there is substantial doubt in our ability to remain in business over the next 12 months. There can be no assurance that any financing will be available to the Company on acceptable terms, or at all. If adequate funds are not available, the Company may be required to delay, scale back or eliminate its research, engineering and development or manufacturing programs or obtain funds through arrangements with partners or others that may require the Company to relinquish rights to certain of its technologies or potential products or other assets. Accordingly, the inability to obtain such financing could have a material adverse effect on the Company's business, financial condition and results of operations.

Management's plans for dealing with the foregoing matters include:

- o Increasing sales of its amplifier products by developing newer products for the Multimedia Broadcast market place through both individual customers, strategic alliances and mergers.
- o Decreasing the dependency on certain major customers by aggressively seeking other customers in the amplifier markets;
- o Partnering with significant companies to jointly develop innovative products, which has yielded orders with multinational companies to date, and which are expected to further expand such relationships;
- o Reducing costs through a more streamlined operation by using automated

Edgar Filing: AMPLIDYNE INC - Form 10QSB

machinery to produce components for our products;

- o Deferral of payments of officers' salaries, as needed;
- o Selling remaining net operating losses applicable to the State of New Jersey, pursuant to a special government high-technology incentive program in order to provide working capital, if possible;
- o Reducing overhead costs and general expenditures.
- o Merging with another company to provide adequate working capital and jointly develop innovative products.

-9-

AMPLIDYNE, INC. NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS JUNE 30, 2004

NOTE G - OFFICER LOANS

As of June 30, 2004, the Company owes \$268,101 to the now former Chief Executive Officer for loans and unpaid salaries. During the six months ended June 30, 2004, the Chief Executive Officer advanced \$18,000 to the Company. Additionally, salaries of \$23,192 were deferred for this quarter

NOTE H - SEGMENT INFORMATION

The Company commenced its wireless Internet connectivity business in the summer of 2000. The Company does not measure its operating results, assets or liabilities by segment. However, the following limited segment information is available:

	Six Months Ended June 30 2004 -----	Six Months Ended June 30 2003 -----	Year Ended December 31, 2003 -----
Sales - external			
Amplifier	\$ 512,134	743,274	\$1,128,453
Internet business	43,459	130,238	222,772
	-----	-----	-----
	\$ 555,593	\$ 873,512	\$1,351,225
	=====	=====	=====
Inventory	--		
Amplifier	\$ 232,513	\$ 409,317	\$ 248,575
Internet business	116,007	494,688	159,134
	-----	-----	-----
	\$ 348,520	\$ 904,005	\$ 407,709
	=====	=====	=====

NOTE I -- OTHER COMMENTS

Edgar Filing: AMPLIDYNE INC - Form 10QSB

1. NOTICE OF OPPOSITION ON TRADEMARK

The Company's registration of the Ampwave trademark was opposed at the U.S. Patent Office. The Company has settled with the opposing party by agreeing to stop using the Ampwave name after a period of one (1) year from the date of signing. Sales under the Ampwave label were \$43,459 for the three months ended June 30, 2004. Management believes that the settlement will have no material financial effect.

NOTE J - SUBSEQUENT EVENT

Effective August 19, 2004, Devendar S. Bains stepped down from his position as Chairman of the Board, Chief Executive Officer and President and is now the Chief Technology Officer. Tarlochan Bains has taken over the position of Chairman of the Board and Chief Executive Officer.

-10-

AMPLIDYNE, INC.

PART I - FINANCIAL INFORMATION

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS - THE THREE MONTHS ENDED JUNE 30, 2004 COMPARED TO THREE MONTHS ENDED JUNE 30, 2003.

Revenues for the three months ended June 30, 2004 declined by \$123,678 from \$363,904 to \$240,226, or 34% compared to the three months ended June 30, 2003. The sales decrease were primarily in amplifiers.

The majority of the amplifier sales for the three months ended June 30, 2004 were obtained from the Wireless Local Loop amplifier products to a major European customer. Sales of amplifiers were approximately 93% of total sales compared to 85% of total sales for the same period last year. The Ampwave high speed wireless Internet products and broadband solutions accounted for approximately 7% of total sales, against 15% of total sales for the same period last year.

The Company has continued to develop and refine its amplifier products for the wireless communications market. The Company has also refined its wireless internet products. Sales and marketing efforts have been focused in the more stable United States, European and Canadian markets.

Cost of sales was \$223,367 or 93% of sales compared to 77% during the same period for 2003. Gross margin for the three months ended June 30, 2004 amounted to \$16,859 (7%) compared to \$84,979 (23%), for the same period ended June 30, 2003. The decline in gross margin was principally due to pricing pressures in the telecommunications sector.

Selling, general and administrative expenses (excluding stock based compensation) decreased in 2004 by \$107,907 to \$109,033 from \$216,940, in 2003. Expressed as a percentage of sales, the selling, general and administrative expenses (excluding stock based compensation) were 45% in 2004 and 39% in 2003. The principal factors contributing to the decrease in selling, general and administrative expenses were related to the effects of our cost cutting program implemented in 2002. In the quarter ended June 30, 2004, we continued to maintain the lower staffing and overhead levels that we instituted in 2002.

Edgar Filing: AMPLIDYNE INC - Form 10QSB

Research, engineering and development expenses were 35% of net sales for the three months ended June 30, 2004 compared to 27% in 2003. In 2004 and 2003, the principal activity of the business related to the design and production of product for OEM manufacturers, particularly for the IMT 2000 and 3.5 GHz single channel products and refinements to the High Speed Internet products. The research, engineering and development expenses consist principally of salary cost for engineers and the expenses of equipment purchases specifically for the design and testing of the prototype products. The Company's research and development efforts are influenced by available funds and the level of effort required by the engineering staff on customer specific projects.

-11-

AMPLIDYNE, INC.

Interest income was \$NIL in 2004 and 2003 because our cash balances which we have historically temporarily invested in interest bearing accounts have been fully depleted.

Interest expense was \$600 in 2004 compared to \$69 in 2003 and was principally related to financing costs in connection with the Phoenix rescission.

As a result of the foregoing, the Company incurred net losses of \$(239,798) or \$(0.02) per share for the quarter ended June 30, 2004 compared with net losses of \$(230,032) or \$(0.02) per share for the same quarter in 2003.

RESULTS OF OPERATIONS - THE SIX MONTHS ENDED JUNE 30, 2004 COMPARED TO SIX MONTHS ENDED JUNE 30, 2003.

Revenues for the six months ended June 30, 2004 declined by \$317,919 from \$873,512 to \$555,593, or 36% compared to the six months ended June 30, 2003.

The majority of the amplifier sales for the six months ended June 30, 2004 were obtained from the Wireless Local Loop amplifier products to a major European customer.

The Company has continued to develop and refine its amplifier products for the wireless communications market. The Company has also refined its wireless internet products. Sales and marketing efforts have been focused in the more stable United States, European and Canadian markets.

Cost of sales was \$511,767 or 92% of sales compared to \$557,783 or 64% of sales during the same period for 2003. The decline in gross margin was principally due to pricing pressures in the telecommunications sector. The Company is continuing to assess cost reduction and is promoting increased product demand to improve gross margins in 2004.

Selling, general and administrative expenses (excluding stock based compensation) decreased in 2004 by \$88,565 to \$322,106 from \$410,671, in 2003. Expressed as a percentage of sales, the selling, general and administrative expenses (excluding stock based compensation) were 58% in 2004 and 47% in 2003. The principal factors contributing to the decrease in selling, general and administrative expenses were related to the effects of our cost cutting program implemented in 2002. In the quarter ended June 30, 2004, we continued to maintain the lower staffing and overhead levels that we instituted in 2002.

Research, engineering and development expenses were 29% of net sales for the six months ended June 30, 2004 compared to 22% in 2003. In 2004 and 2003, the

Edgar Filing: AMPLIDYNE INC - Form 10QSB

principal activity of the business related to the design and production of product for OEM manufacturers, particularly for the IMT 2000 and 3.5 GHz single channel products and refinements to the High Speed Internet products. The research, engineering and development expenses consist principally of salary cost for engineers and the expenses of equipment purchases specifically for the design and testing of the prototype products. The Company's research and development efforts are influenced by available funds and the level of effort required by the engineering staff on customer specific projects.

The Company had interest income and other income in 2003 of \$2. Interest income was \$NIL in 2004 because our cash balances which we have historically temporarily invested in interest bearing accounts have been fully depleted.

As a result of the foregoing, the Company incurred net losses of \$504,862 or \$0.05 per share for the six months ended June 30, 2004 compared with net losses of \$290,222 or \$0.03 per share for the same period in 2003.

-12-

AMPLIDYNE, INC.

ITEM 3. LIQUIDITY AND CAPITAL RESOURCES

Liquidity refers to our ability to generate adequate amounts of cash to meet our needs. We have been generating the cash necessary to fund our operations from continual loans from the former President and Chief Executive Officer of the Company, Devendar Bains. We have incurred a loss in each year since inception. We expect to incur further losses, that the losses may fluctuate, and that such fluctuations may be substantial. As of June 30, 2004 we had an accumulated deficit of \$23,435,035. Potential immediate sources of liquidity are loans in connection with the Convertible Notes.

As of June 30, 2004, our current liabilities exceeded our cash and receivables by \$1,310,631. Our current ratio was 0.30 to 1.00, but our ratio of accounts receivable to current liabilities was only 0.05 to 1.00. This indicates that we will have difficulty meeting our obligations as they come due. We are carrying \$348,520 in inventory, of which \$299,418 represents component parts. Based on year to date usage, we are carrying 286 days worth of parts inventory. Because of the lead times in our manufacturing process, we will likely need to replenish many items before we use everything we now have in stock. Accordingly, we will need more cash to replenish our component parts inventory before we are able realize cash from all of our existing inventories.

As of June 30, 2004, we had cash of \$15,465 compared to an overdraft of \$17,855 at December 31, 2003. Overall our cash increased \$33,320 during 2004. Our cash used for operating actives was \$76,681. This year we received loans of \$18,000 and deferred salary payments to officer/stockholders of \$55,233. We also received proceeds from the issuance of convertible promissory notes of \$93,000.

The allowance for doubtful accounts on trade receivables increased from \$143,000 (61% of accounts receivable of \$234,482) in 2003 to \$262,000 (82% of accounts receivable of \$319,854) in 2004. Additionally, in 2003, we reserved an aggregate of \$31,702 against leases that appear to be uncollectible. Because of our relatively small number of customers and low sales volume, accounts receivable balances and allowances for doubtful accounts do not reflect a consistent relationship to sales. We determine our allowance for doubtful accounts based on a specific customer-by-customer review of collectibility.

Our inventories decreased by \$59,189 to \$348,520 in 2004 compared to \$407,709 at

Edgar Filing: AMPLIDYNE INC - Form 10QSB

December 31, 2003, a decrease of 15%.

The Company has several lease obligations for its premises and certain equipment requiring minimum monthly payments of approximately \$9,800 through 2005. Although the Company did not convert salaries to officers through the issuance of Common Stock in 2004 or 2003, it may do so in 2004. To help alleviate the cash flow difficulties, the Chief Executive Officer and the Vice President of Operations agreed to additional salary deferrals of \$46,384 and \$5,538, respectively.

The Company continues to explore strategic relationships with ISP's, customers and others, which could involve jointly developed products, revenue-sharing models, investments in or by the Company, or other arrangements. There can be no assurance that a strategic relationship can be consummated.

In the past, the officers of the Company have deferred a portion of their salaries or provided loans to the Company to meet short-term liquidity requirements. Where possible, the Company has issued stock or granted warrants to certain vendors in lieu of cash payments, and may do so in the future. There can be no assurance that any additional financing will be available to the Company on acceptable terms, or at all. If adequate funds are not available, the Company may be required to delay, scale back or eliminate its research, engineering and development or manufacturing programs or obtain funds through arrangements with partners or others that may require the Company to relinquish rights to certain of its technologies or potential products or other assets. Accordingly, the inability to obtain such financing could have a material adverse effect on the Company's business, financial condition and results of operations.

-13-

AMPLIDYNE, INC.

With little remaining cash and no near term prospects of private placements, options or warrant exercises (other than the Convertible Notes) and reduced revenues, we believe that we will have great difficulty meeting our working capital needs over the next 12 months. We are presently dependent on cash flows generated from sales and loans in connection with the Convertible Notes. Our failure to substantially improve our revenues will have serious adverse consequences and, accordingly, there is substantial doubt in our ability to remain in business over the next 12 months. There can be no assurance that adequate additional financing will be available to the Company on acceptable terms, or at all. If adequate funds are not available, the Company may be required to delay, scale back or eliminate its research, engineering and development or manufacturing programs or obtain funds through arrangements with partners or others that may require the Company to relinquish rights to certain of its technologies or potential products or other assets. Accordingly, the inability to obtain such financing could have a material adverse effect on the Company's business, financial condition and results of operations.

CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including the former Chief Executive and Principal Accounting officer, we have evaluated the effectiveness of the design and operation of our disclosure controls pursuant to Exchange Act Rule 13a-14(c) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive and Principal Accounting Officer concluded that the Company's disclosure controls and procedures are effective in timely alerting him to material information required

Edgar Filing: AMPLIDYNE INC - Form 10QSB

to be included in the Company's periodic SEC filings relating to the Company. There were no significant changes in the Company's internal controls or in other factors that could significantly affect these internal controls subsequent to the date of my most recent evaluation.

Our management, including the former Chief Executive and Principal Accounting officer, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their cost. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud within the Company, if any, will be detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that a breakdown can occur because of a simple error. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

-14-

AMPLIDYNE, INC.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note E to the Company's financial statements set forth in Part I.

*

ITEM 2. CHANGES IN SECURITIES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) The following is a list of exhibits to this Form 10-QSB:

* Certification of the Company's Chief Executive and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

* Certification of the Company's Chief Executive and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K

None.

-15-

Edgar Filing: AMPLIDYNE INC - Form 10QSB

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMPLIDYNE, INC.

Dated: August 23, 2004

By: /S/ TARLOCHAN. BAINS

Name: Tarlochan. Bains
Title: Chief Executive Officer,
Treasurer, Principal
Accounting Officer and Director